Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.

Diabetes, obesity & metabolism·2026
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Safety and Effectiveness of MiniMedâ„¢ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial.

Journal of the American College of Cardiology·2026
Same author

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Journal of the American Society of Nephrology : JASN·2026

Related Experiment Video

Updated: Apr 7, 2026

Intraportal Transplantation of Pancreatic Islets in Mouse Model
09:01

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

10.4K

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.

Bruce W Bode1, Janet B McGill2, Daniel L Lorber3

  • 1Atlanta Diabetes Associates, Atlanta, GA bbode001@aol.com.

Diabetes Care
|July 17, 2015
PubMed
Summary
This summary is machine-generated.

Technosphere insulin (TI) demonstrated noninferior HbA1c reduction compared to insulin aspart in type 1 diabetes patients. TI showed less hypoglycemia and weight gain, but a higher incidence of cough.

More Related Videos

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.5K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

Intraportal Transplantation of Pancreatic Islets in Mouse Model
09:01

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

10.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.5K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Trials

Background:

  • Type 1 diabetes management requires effective glycemic control.
  • Insulin therapy is central to type 1 diabetes treatment.
  • Comparing novel insulin formulations with established ones is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate the efficacy and safety of Technosphere insulin (TI) versus insulin aspart in type 1 diabetes.
  • To determine if TI is noninferior to insulin aspart in reducing HbA1c.
  • To assess safety profiles, including hypoglycemia and adverse events, for both insulin types.

Main Methods:

  • An open-label, noninferiority trial was conducted.
  • Participants with type 1 diabetes and HbA1c 7.5-10.0% received either prandial TI or subcutaneous aspart with basal insulin.
  • Changes in HbA1c from baseline to 24 weeks were compared between groups.

Main Results:

  • HbA1c reduction with TI was noninferior to insulin aspart (mean change -0.21% vs. -0.40%).
  • TI group experienced significantly lower rates of hypoglycemia and less weight gain compared to the aspart group.
  • Cough was more frequent in the TI group (31.6%) versus the aspart group (2.3%), leading to discontinuation in some TI patients.

Conclusions:

  • Technosphere insulin (TI) offers noninferior HbA1c reduction compared to insulin aspart in type 1 diabetes.
  • TI presents a favorable safety profile with reduced hypoglycemia and weight gain.
  • Increased cough incidence with TI requires consideration in clinical practice.